       Document 0198
 DOCN  M9630198
 TI    Recombinant erythropoietin for zidovudine-induced anemia in AIDS.
 DT    9603
 AU    Kuehl AK; Noormohamed SE; Department of Preventive Medicine, College of
       Medicine,; University of Iowa, Iowa City 52242, USA.
 SO    Ann Pharmacother. 1995 Jul-Aug;29(7-8):778-9. Unique Identifier :
       AIDSLINE MED/96131197
 AB    Recombinant erythropoietin (Epogen, Amgen Pharmaceuticals; Procrit,
       Amgen Pharmaceuticals, distributed by Ortho Biotech) is approved for use
       in anemia associated with HIV infection and treatment. The recommended
       starting dose is 100 IU/kg iv or sc 3 times per week. Current evidence
       suggests that anemia in zidovudine-treated patients may be a result of
       insufficient quantities of erythropoietin, bone marrow unresponsiveness
       to the hormone, or HIV infection. Among patients receiving zidovudine, a
       review of the available data suggests that baseline serum erythropoietin
       concentrations may aid in predicting the response to exogenous hormone
       administration.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY
       Anemia/CHEMICALLY INDUCED/*DRUG THERAPY  Erythropoietin/*THERAPEUTIC USE
       Human  Recombinant Proteins/THERAPEUTIC USE  Zidovudine/*ADVERSE EFFECTS
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

